Connection

Viroj Wiwanitkit to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications Viroj Wiwanitkit has written about Cost-Benefit Analysis.
Viroj Wiwanitkit
Connection Strength
1.025
Cost-Benefit Analysis
  1. New COVID-19 Vaccines, Its Cost and Shelf Life: A Cost Effectiveness Analysis. Arch Med Res. 2021 05; 52(4):453.
    View in: PubMed
    Score: 0.423
  2. Cost Effectiveness Analysis Comparing PCR Versus IgG Test for Initial COVID-19 Screening. Clin Lab. 2021 05 01; 67(5).
    View in: PubMed
    Score: 0.108
  3. Re: HPV vaccination for penile cancer eradication: cost effectiveness view. Int Braz J Urol. 2019 Jan-Feb; 45(1):199-200.
    View in: PubMed
    Score: 0.092
  4. Cryptococcal antigenemia screening among human immunodeficiency virus-infected cases with tuberculosis: Chance and cost effectiveness. Int J Mycobacteriol. 2018 Oct-Dec; 7(4):395-396.
    View in: PubMed
    Score: 0.091
  5. Comparison between adjuvanted and nonadjuvanted influenza vaccination among patients undergoing hemodialysis: A cost-effectiveness analysis from Thailand. Saudi J Kidney Dis Transpl. 2018 Mar-Apr; 29(2):474-475.
    View in: PubMed
    Score: 0.087
  6. Cost-effectiveness analysis of common tuberculosis screening laboratory tests for hemodialysis patients: An analysis from tropical endemic country, Thailand. Saudi J Kidney Dis Transpl. 2018 Mar-Apr; 29(2):476-477.
    View in: PubMed
    Score: 0.087
  7. Cost analysis for renal dialysis: Case study from Indochina. Saudi J Kidney Dis Transpl. 2017 Jul-Aug; 28(4):948.
    View in: PubMed
    Score: 0.083
  8. Stool occult blood testing: comparison. Am J Gastroenterol. 2010 Dec; 105(12):2709.
    View in: PubMed
    Score: 0.053
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.